Anon Fish is Correct on Both Accounts
Amarin Management has been consistent in indicating that they are in no rush to submit the sNDA, so it will be submitted towards the very end of their consistent guidance of 1st Quarter 2019, which is 6 months after Reduce It results came out on 9/24/2018.
Amarin Management have yet to indicate that they WILL request expedited review and it is possible they will not. Since Amarin Management has not expedited their sNDA submittal and if they don't request expedited review, it is very possible FDA will not expedite their review and take till the end of 2019 to give their approval or disapproval. Amarin Management has also been very consistent in indicating that FDA's review may take till the end of 2019, which is potentially another indicator that they will not request expedited review.
This gives shorts/MM/Hedge Funds/BP lots of time to monkey around with AMRN share price.
It also gives Amarin Management time to "justify" more stock dilution, since script sales may not be expanding as fast as they would have liked because insurance companies are not covering Vascepa because of no FDA approval, and to reward themselves with more free shares
I really hope the above proves to be untrue but much of it is consistent with the guidance provided by Amarin Management.
News 
Market Data 
Discover 
